Seeking Alpha·Oct 13, 2026
BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks TranscriptBeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript
BeyondSpring remains a high-risk, pre-commercial entity characterized by a lack of recurring revenue and a rapidly depleting capital base. The company's reliance on speculative milestone payments and the failure to secure FDA approval for its lead asset, Plinabulin, create significant regulatory and liquidity…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.02+96.3% vs -$0.54 | — vs $9M |
Q2 2026 May 13, 2026 | -$0.05+90.7% vs -$0.54 | — vs $9M |
Q2 2026 Mar 25, 2026 | -$0.05+90.3% vs -$0.54 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.05 vs — | — vs — |
BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript
BeyondSpring (NASDAQ: BYSI) said the U.S. Food and Drug Administration has granted Fast Track designation to plinabulin in combination with docetaxel for patients with second- or third-line non-squamous non-small cell lung cancer (NSCLC) who have progressed after immune checkpoint inhibitor treatment and platinum-based chemotherapy and do not have actionable genomic alterations. The company also disclosed a
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) without actionable genomic alterations (AGAs) whose disease has progressed following prior anti-PD-(L)1 antibody therapy and platinum-based chemotherapy, representing patients in the second- or third-line treatment setting. This is the patient population being studied in BeyondSpring's global Phase 3 DUBLIN-4 trial.
Benchmark BYSI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BeyondSpring Inc. (BYSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.63 | $25.74M | -3.85 | — | — | — | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
BeyondSpring Inc. (BYSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BeyondSpring Inc. (BYSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jun 4, 2026·SEC
May 13, 2026·SEC
Get notified when BYSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BeyondSpring Inc. (BYSI) stock FAQ — growth, dividends, profitability & financials explained
BeyondSpring Inc. (BYSI) grew revenue by 100.0% over the trailing twelve months, compared with the twelve months before.
No. BeyondSpring Inc. (BYSI) reported a net loss of $6.7M over the trailing twelve months.
BeyondSpring Inc. (BYSI) had negative free cash flow of $17.1M over the trailing twelve months.
